386 related articles for article (PubMed ID: 32077754)
1.
Bai H; Zhou M; Zeng M; Han L
DNA Cell Biol; 2020 Apr; 39(4):700-708. PubMed ID: 32077754
[TBL] [Abstract][Full Text] [Related]
2. Identifying a novel 5-gene signature predicting clinical outcomes in acute myeloid leukemia.
Sha K; Lu Y; Zhang P; Pei R; Shi X; Fan Z; Chen L
Clin Transl Oncol; 2021 Mar; 23(3):648-656. PubMed ID: 32776271
[TBL] [Abstract][Full Text] [Related]
3. A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML.
Hassan JJ; Lieske A; Dörpmund N; Klatt D; Hoffmann D; Kleppa MJ; Kustikova OS; Stahlhut M; Schwarzer A; Schambach A; Maetzig T
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502319
[No Abstract] [Full Text] [Related]
4. [Clinical Significance of Low Expression of LncRNA CASC15 in Acute Myeloid Leukemia with NPM1 Mutations].
Xia PH; Xu ZJ; Jin Y; Ma JC; Wen XM; Yuan Q; Leng JY; Qian J; Lin J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):659-670. PubMed ID: 35680788
[TBL] [Abstract][Full Text] [Related]
5. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
[TBL] [Abstract][Full Text] [Related]
7. High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia.
Li K; Chen L; Zhang H; Wang L; Sha K; Du X; Li D; Zheng Z; Pei R; Lu Y; Tong H
Aging (Albany NY); 2021 Apr; 13(8):11988-12006. PubMed ID: 33891561
[TBL] [Abstract][Full Text] [Related]
8. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia.
Damm F; Oberacker T; Thol F; Surdziel E; Wagner K; Chaturvedi A; Morgan M; Bomm K; Göhring G; Lübbert M; Kanz L; Fiedler W; Schlegelberger B; Heil G; Schlenk RF; Döhner K; Döhner H; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Feb; 29(6):682-9. PubMed ID: 21205756
[TBL] [Abstract][Full Text] [Related]
9. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
[TBL] [Abstract][Full Text] [Related]
10. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
[TBL] [Abstract][Full Text] [Related]
11. Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.
Qu X; Othus M; Davison J; Wu Y; Yan L; Meshinchi S; Ostronoff F; Estey EH; Radich JP; Erba HP; Appelbaum FR; Fang M
Cancer; 2017 Jul; 123(13):2472-2481. PubMed ID: 28222251
[TBL] [Abstract][Full Text] [Related]
12. Selection of three miRNA signatures with prognostic value in non-M3 acute myeloid leukemia.
Xue Y; Ge Y; Kang M; Wu C; Wang Y; Rong L; Fang Y
BMC Cancer; 2019 Jan; 19(1):109. PubMed ID: 30700251
[TBL] [Abstract][Full Text] [Related]
13. miRNA-mRNA Profiling Reveals Prognostic Impact of
Gadewal N; Kumar R; Aher S; Gardane A; Gaur T; Varma AK; Khattry N; Hasan SK
Oncol Res; 2020 May; 28(3):321-330. PubMed ID: 32059753
[TBL] [Abstract][Full Text] [Related]
14. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
15. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.
Jin H; Yang L; Wang L; Yang Z; Zhan Q; Tao Y; Zou Q; Tang Y; Xian J; Zhang S; Jing Y; Zhang L
J Exp Clin Cancer Res; 2018 Jan; 37(1):8. PubMed ID: 29343273
[TBL] [Abstract][Full Text] [Related]
16. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
19. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
[TBL] [Abstract][Full Text] [Related]
20. [NPM1 High Mutant Allele Burden is an Adverse Prognostic Factor for AML Patients with Mutated NPM1].
Hou JX; Wang SJ; Liu YF; Hao QQ; Wang C; Li T; Bai JJ; Liao LX; Guo CY; Chang YY; Wang M; Sun H; Xie XS; Jiang ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):365-372. PubMed ID: 30998139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
